Ethnic Variation in Lipoprotein(a) Levels in the Kazakhstan Population

2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/jcm14176336
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background: Lipoprotein(a) (Lp(a)) is a genetically determined lipoprotein that plays an independent role in the development of atherosclerotic cardiovascular disease (ASCVD). Ethnic differences in Lp(a) levels are well-documented, yet regional data from Central Asia, particularly Kazakhstan, remain scarce. Methods: We conducted a retrospective, single-center study involving 3727 patients aged ≥ 18 years who underwent Lp(a) testing between January 2023 and June 2024. Participants were stratified by self-reported ethnicity and atherosclerosis status confirmed via coronary angiography. Lp(a) levels were analyzed using immunoturbidimetric assays. Results: Elevated Lp(a) levels (≥50 mg/dL) were identified in 19.6% of the total population. While Kazakhs exhibited a slightly higher prevalence of elevated Lp(a) compared to Russians, there were no statistically significant differences in Lp(a) levels across ethnic groups. ROC analysis revealed limited discriminatory power of Lp(a) for diagnosing atherosclerosis (AUC = 0.5464), although PRC analysis showed high sensitivity and precision in both Kazakh and Russian subgroups at lower thresholds. Conclusions: Despite modest ethnic variation in Lp(a) distribution, its predictive value for atherosclerosis remains limited as a standalone marker. These findings highlight the need for population-specific thresholds and support incorporating Lp(a) testing in broader cardiovascular risk assessment strategies in Central Asia.